About this project
There is a worldwide need to identify biomarkers that are specific and enable the diagnosis of chronic disease at an earlier time point. In doing so we can treat patients before their disease affects multiple organs, enabling more effective treatment, extending patient survival and enhancing quality of life. We aim to develop non-invasive or minimally invasive tests to identify early pre-clinical disease changes in patients. This should improve patient outcomes with diminished side effects and decrease NHS treatment costs.
This cluster encompasses academic staff, based in both the School of Life Sciences and the School of Mathematics and Physical Sciences at the University of Hull, who are experienced in biomarker identification in difficult to treat diseases such as endometriosis (Guinn), therapy-induced cancer (Wade), cardiovascular disease (Beltran-Alvarez) and sarcoidosis (Hart). Our skills in state-of-the-art technologies such as lab-on-a-chip (Pamme) and spheroids (Pires), and our access to high tech equipment (mass spectrometry, phosphor-flow cytometry, transcriptomics) provide a unique opportunity to collaborate and form a UK cluster of excellence providing high quality training and mentorship to our PGR students.
Identification of genomic biomarkers for therapy-induced cancer with Mark Wade.
Therapy-induced solid tumours arise as a consequence of the treatment given for primary cancer. Although these malignancies have a well-defined aetiology, the molecular genetic alterations that define these cancers and drive carcinogenesis are not well understood. You will join an ambitious and friendly group aiming to identify and validate common molecular genetic alterations in therapy-induced solid tumours. The strategies used to achieve this aim will be varied, including genome-wide analysis of therapy-induced tumour samples to identify novel genetic alterations, focussed genomic analysis of samples to validate current and identified targets, and functional analysis of alterations in cell line models. Your work will identify alterations that will help to define the genomic landscape of therapy-induced tumours, act as biomarkers for the early detection of therapy-induced cancer, and aid the development of targeted therapeutic regimens.
You are strongly advised to contact a potential supervisor and to discuss your research proposal, well before you submit an application. Please refer to the Health research pages.
If you have any queries, please email Mark Wade.
To celebrate the University's research successes, the University of Hull is offering a full-time UK/EU PhD Scholarship or International Fees Bursary.
Applicants should have at least a 2.1 undergraduate degree in biomedicine or a related discipline, together with relevant research experience. It is anticipated that the successful applicant will have a 1st class undergraduate degree or Masters level qualification.
How to apply
Applications for scholarship consideration at the University of Hull should be made through the Postgraduate Application system.
On the second page of your application, please select “Graduate Scholarship” as the type of scholarship you are applying for.
Applicants are strongly encouraged to first identify and contact a potential supervisor.
Application deadline: Thursday 8th February
Full-time UK/EU PhD Scholarships will include fees at the ‘home/EU' student rate and maintenance (£14,553 in 2017/18) for three years, depending on satisfactory progress.
Full-time International Fee PhD Studentships will include full fees at the International student rate for three years, dependent on satisfactory progress.